SeaStar Medical Announces Receipt Of A Category B Coverage Letter From The U.S. CMS For The NEUTRALIZE-AKI Pivotal Trial Evaluating The Co's Selective Cytopheretic Device In Adults With Acute Kidney Injury
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical Holding Corporation (NASDAQ:ICU) received a Category B Coverage Letter from the U.S. CMS for its NEUTRALIZE-AKI pivotal trial. This will cover a portion of the trial costs and is expected to accelerate medical site activations.

July 16, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SeaStar Medical received a Category B Coverage Letter from the U.S. CMS for its NEUTRALIZE-AKI pivotal trial, which will cover a portion of the trial costs and is expected to accelerate medical site activations.
The CMS coverage will reduce financial burden and accelerate the trial process, which is positive for SeaStar Medical's progress and investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100